|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mir-33a was demonstrated to act as a tumor suppressor in larnygeal cancer via directly targeting the 3' untranslated region of PIM1.
|
30102806 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings warrant clinical evaluation of PIM kinase inhibitors in patients with TN tumors that have elevated MYC expression.
|
27775705 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, when samples of primary tumor and metastasis retrieved from the same patients (n=26) were analyzed, nearly significant correlation of Pim-1 expression with histological grade was found (p=0.06).
|
17487358 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment with PIM kinase inhibitors reverses this resistance phenotype, making tumors increasingly susceptible to small-molecule therapeutics, which block the PI3K-AKT pathway.
|
30190422 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PIM family of oncogenic serine/threonine kinases regulates tumour cell proliferation.
|
22193779 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma.
|
28698206 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We investigated the immunohistochemical expression of PIM-1 kinase in 35 samples of soft tissue tumours using tissue microarray technology and 49 full sections of adipocytic (n = 26) and non-adipocytic tumours (n = 23).
|
19878356 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
|
24799066 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further, immunohistochemical staining, which was performed in 20 randomly selected BCL6-positive human B- and T-cell lymphomas, revealed concurrent expression of BCL6 and PIM1 in these neoplasms.
|
22451912 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo experiments further confirmed that knockdown of Pim1 inhibits the growth of tumors derived from the SKOV3 cell line.
|
30349298 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present work, we review the importance of PIM kinases in tumor growth and as drug targets.
|
23576269 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PIM1, a serine/threonine kinase, plays an essential role in tumorigenesis of multiple types of tumors.
|
30464610 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of PIM1 experimentally leads to tumor formation in mice, while complete knockout of the protein has no observable phenotype.
|
20919829 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This review highlights the enhanced activity of PIM kinases in cancer that can be driven by hypoxia in the tumour microenvironment and the important role that aberrant PIM kinase activity plays in resistance mechanisms to chemotherapy, radiotherapy, anti-angiogenic therapies and targeted therapies.
|
31836451 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The rationale for this therapeutic approach is based on the fact that antiangiogenic drugs can make tumors hypoxic, and thus more sensitive to PIM inhibitors.<b>Experimental Design:</b> Xenograft and orthotopic models of prostate and colon cancer were used to assess the effect of PIM activation on the efficacy of VEGF-targeting agents.
|
29084916 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The bcr-abl/M-induced tumors also showed recurring proviral integration near c-myc, Pim-1 and Mlvi-1, albeit at a lower frequency than seen in the Mo-MuLV tumors.
|
9204986 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, both PIM kinases have a reported synergistic effect with c-MYC in mediating tumour development in several cancers, c-MYC gene being translocated to one of the immunoglobulin loci in nearly all BLs.
|
26643319 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Twelve tumors with matching normal renal tissue implicated increased PIM's and MAPKAPK's in tumors compared to adjacent normal renal tissue.
|
26406598 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We studied the expression and genomic status of PIM1 in human primary gastric normal and tumor tissue samples by immunohistochemistry and array-based comparative genomic hybridization (aCGH).
|
21993851 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Murine melanoma B16 was established subcutaneously and treated by transferring tumor epitope gp100-reactive T cells along with treatment regimen that involved inhibiting PIM kinases, anti-PD1 or both.
|
30327305 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pim1-silenced cells were more vulnerable to glucose starvation, and Pim1-induced tumor proliferation or tolerance to glucose starvation was attenuated by blocking the Warburg effect.
|
29516572 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These compounds induce tumour cell death and enhance cytotoxicity with chemotherapeutic agents and targeted compounds, including PIM kinase inhibitors.
|
29045385 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Depletion of PIM1 decreased cell proliferation, migration, invasion and colony formation in vitro, as well as reduced tumor growth in vivo.
|
30583073 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The possible end-point is an increased percentage of cancer stem cells, which may be partly responsible for the therapy resistance found in tumors overexpressing PIM kinases.
|
28938604 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PIM-1 expression levels were significantly associated with tumor size, lymph node involvement, nerve invasion, distant metastasis and weakly associated with tumor node metastasis stage.
|
29399171 |
2018 |